 OBJECTIVES: I. Assess the value in terms of disease-free survival and overall survival of short intensive consolidation with high-dose cytosine arabinoside in patients with acute myelogenous leukemia who achieve complete remission after induction with daunorubicin and cytosine arabinoside. II. Assess the toxicity and resulting quality of life associated with consolidation with high-dose cytosine arabinoside compared with conventional consolidationmaintenance treatment. III. Determine whether addition of granulocyte-macrophage colony stimulating factor GM-CSF to Induction chemotherapy can improve therapeutic results through activation of leukemic cells into the cell cycle andor acceleration of hematopoietic recovery objective added 0890. IV. Determine indirectly whether autologous bone marrow therapy is better than conventional consolidationmaintenance or high-dose cytosine arabinoside by comparing results from protocol EORTC-06863 AML 8 A. 